Pharma BD Deal Intelligence
Abbott's $27/share Facet bid topped Biogen's failed $17 hostile offer by 67% — analysts framed the outcome as Facet's board correctly rejecting Biogen's…
Abbott's Facet acquisition added a Phase III-ready MS biologic and four mid-stage oncology candidates plus an antibody engineering platform — viewed as a…
Daclizumab (Zinbryta) was voluntarily withdrawn globally in March 2018 by Biogen and AbbVie after EMA flagged 'serious and potentially fatal immune reactions'…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Abbott to acquire Facet Biotech for $27/share cash (~$722M gross, ~$450M net of Facet's cash). Adds daclizumab Phase II MS biologic and oncology compounds. Closed April 21, 2010.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Facet Biotech Corporation (this deal) | 2010 | $722M | 33 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
← Browse all deals · How we score deals
More: 2010 deals · Abbott Laboratories deals · Neurology deals